S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   443.97 (-0.19%)
AAPL   171.41 (-1.10%)
MSFT   420.72 (-0.17%)
META   485.90 (-1.61%)
GOOGL   150.80 (-0.05%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   443.97 (-0.19%)
AAPL   171.41 (-1.10%)
MSFT   420.72 (-0.17%)
META   485.90 (-1.61%)
GOOGL   150.80 (-0.05%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   443.97 (-0.19%)
AAPL   171.41 (-1.10%)
MSFT   420.72 (-0.17%)
META   485.90 (-1.61%)
GOOGL   150.80 (-0.05%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   443.97 (-0.19%)
AAPL   171.41 (-1.10%)
MSFT   420.72 (-0.17%)
META   485.90 (-1.61%)
GOOGL   150.80 (-0.05%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:VTVT

vTv Therapeutics (VTVT) Stock Price, News & Analysis

$23.53
-0.27 (-1.13%)
(As of 04:00 PM ET)
Today's Range
$22.81
$25.07
50-Day Range
$7.87
$29.00
52-Week Range
$7.38
$39.60
Volume
13,672 shs
Average Volume
77,748 shs
Market Capitalization
$70.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
VTVT stock logo

About vTv Therapeutics Stock (NASDAQ:VTVT)

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

VTVT Stock Price History

VTVT Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
vTv Therapeutics Inc. (VTVT)
Nasdaq Down 50 Points; US Crude Stocks Rise By 4.2M Barrels
vTv Therapeutics Inc. Cl A
vTv Therapeutics Inc (VTVT)
vTv Therapeutics Inc - Ordinary Shares - Class A
See More Headlines
Receive VTVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2023
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VTVT
Employees
16
Year Founded
N/A

Profitability

Net Income
$-20,250,000.00
Pretax Margin
-306,833.34%

Debt

Sales & Book Value

Annual Sales
$2.02 million
Book Value
($9.27) per share

Miscellaneous

Free Float
2,959,000
Market Cap
$70.83 million
Optionable
Not Optionable
Beta
0.51
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Paul J. Sekhri M.Sc. (Age 66)
    CEO, President & Director
    Comp: $483.43k
  • Mr. Steven Tuch M.B.A. (Age 55)
    Executive VP & CFO
    Comp: $449.16k
  • Mr. Barry Brown (Age 63)
    Chief Accounting Officer
    Comp: $311.98k
  • Mr. Richard S. Nelson (Age 53)
    Executive VP of Corporate Development & Director
    Comp: $201.08k
  • Dr. Carmen Valcarce Ph.D.
    Chief Scientific Officer & Executive VP
  • Vanessa McDade
    Chief Administrative Officer
  • Ms. Elizabeth M. Keiley (Age 58)
    Executive VP & General Counsel
  • Dr. Thomas Strack M.D.
    Ph.D., Chief Medical Officer

VTVT Stock Analysis - Frequently Asked Questions

How have VTVT shares performed in 2024?

vTv Therapeutics' stock was trading at $11.50 at the beginning of the year. Since then, VTVT stock has increased by 104.6% and is now trading at $23.53.
View the best growth stocks for 2024 here
.

Are investors shorting vTv Therapeutics?

vTv Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 57,200 shares, an increase of 50.5% from the February 29th total of 38,000 shares. Based on an average trading volume of 75,100 shares, the days-to-cover ratio is presently 0.8 days. Currently, 10.9% of the company's stock are short sold.
View vTv Therapeutics' Short Interest
.

When is vTv Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VTVT earnings forecast
.

How were vTv Therapeutics' earnings last quarter?

vTv Therapeutics Inc. (NASDAQ:VTVT) posted its quarterly earnings data on Monday, March, 6th. The biotechnology company reported ($2.40) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($2.40). The biotechnology company earned $0.01 million during the quarter.

When did vTv Therapeutics' stock split?

vTv Therapeutics shares reverse split on Tuesday, November 21st 2023. The 1-40 reverse split was announced on Tuesday, November 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of vTv Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), Vaxart (VXRT), Agile Therapeutics (AGRX) and Idera Pharmaceuticals (IDRA).

When did vTv Therapeutics IPO?

vTv Therapeutics (VTVT) raised $125 million in an IPO on Thursday, July 30th 2015. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

Who are vTv Therapeutics' major shareholders?

vTv Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (0.90%) and Vanguard Group Inc. (0.90%). Insiders that own company stock include John A Fry and Ronald O Perelman.
View institutional ownership trends
.

How do I buy shares of vTv Therapeutics?

Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VTVT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners